Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Exploring the link between gut bacteria and spondyloarthritis

Official title: The Role of Dysbiosis of Intestinal Microbiota in the Development of Spondyloarthritis

Run by Assistance Publique - Hôpitaux de Paris · NCT04853212 · Data updated 2026-11-12

This study is testing if a specific gut bacteria called Ruminococcus gnavus is linked to spondyloarthritis by comparing patients with the condition to healthy people.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorAssistance Publique - Hôpitaux de Paris
Academic / other
Locations1 site (Boulogne-Billancourt)
StatusRecruiting
StartedJune 14, 2021
Main results expectedMay 2026
Study endsMay 2026
Registry record updatedMarch 19, 2025
Trial IDNCT04853212 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults diagnosed with spondyloarthritis and those undergoing digestive endoscopy for unrelated reasons.

Probably not a fit

Patients who are pregnant, breastfeeding, or have taken antibiotics recently may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This case-control study investigates the role of the bacterium Ruminococcus gnavus in the development of spondyloarthritis by comparing patients with the condition to healthy controls. It involves intestinal biopsies and fecal sampling to assess the abundance of R. gnavus and its interactions with intestinal mucus and epithelial cells. The study also aims to correlate gene expression in intestinal mucus with variations in microbiota and to demonstrate immune response perturbations caused by dysbiosis.

Why it matters

Potential benefit: If successful, this study could lead to new insights into the role of gut microbiota in spondyloarthritis, potentially guiding future treatments.

How similar studies have gone: While the role of gut microbiota in various conditions has been explored, this specific investigation into R. gnavus and spondyloarthritis is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Patients with SPA:

* Patients ⩾ 18 years;
* Diagnosed as spondyloarthritis (SpA) according ASAS classification;
* Affiliated to a social security scheme;
* Have signed the written informed consent form.

Control subjects:

* Subjects ⩾ 18 years;
* Subjects free of SPA and planned for a digestive endoscopy for another indication such as to explore the risk of colorectal cancer in family member;
* Affiliated to a social security scheme;
* Have signed the written informed consent form.

Exclusion Criteria:

* Subjects unable to understand the proposed study and/or sign a informed consent form;
* Pregnant women or breast feeding women;
* Subjects under guardianship or curatorship;
* Have taken antibiotic 1 month prior to inclusion;
* Presenting acute or chronic severe pathology may likely to interfere with the interpret of outcome;
* Refusal of subjects to participate to the study;
* Foreign patients under french AME scheme.

Where it's running

  • Service de Rhumatologie, Hôpital Ambroise Paré, APHP
    Boulogne-Billancourt, France
    Recruiting

Study contacts

  • Principal investigator: Maxime BREBAN, MD, PhD — Service de Rhumatologie, Hôpital Ambroise Paré, APHP
  • Study coordinator: Maxime BREBAN, MD, PhD
  • Email: maxime.breban@aphp.fr
  • Phone: +33 1 49 09 56 72

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.